BioSpace News Archive

Sintalica Bioscience Corp. (“Sintalica” or the “Company”), a drug discovery company focused on breakthrough treatments for neuroinflammatory disorders, today announced that the Company has achieved two important milestones through the University of Messina (the “University”).

Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced the appointments of Darren Cline and Thomas McCourt to its Board of Directors.

Surmodics, Inc. today announced that management will participate in the following upcoming investor conferences.

Inogen, Inc. today announced that management will participate in a virtual fireside chat at the KeyBanc Virtual Life Sciences & MedTech Investor Forum on Tuesday, March 21, 2023 at 2:15 p.m. Eastern Time.

AIM ImmunoTech Inc. today announced the publication of a new analysis of the ability of AIM’s drug Ampligen (rintatolimod) to inhibit the spread and replication of Ebola virus disease, which adds to the body of evidence supporting Ampligen’s potential as an early-onset prophylactic therapy against human Ebola outbreaks.

Caira Surgical, the pioneer in radar surgical tracking for navigated and robotic joint replacement surgery, unveiled its revolutionary new technology for advanced joint replacement, the Caira TKA Radar Navigation System, during the CG 2023 Musculoskeletal Conference presentation by Caira’s Chief Executive Officer Jon Greenwald.

Editas Medicine, Inc., a clinical-stage genome editing company, announced the appointment of Linea Aspesi as the Company’s Executive Vice President and Chief People Officer.

Infusion Associates (IA), one of the Midwest’s leading providers of medically prescribed outpatient infusion and injection therapies, completed their first Briumvi™ (ublituximab-xiiy) infusion treatment for a patient at their Plymouth, Minnesota location.

Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, today announced that an article was recently published in Epilepsia showed that perampanel reduces seizures with high effectivity in patients with rare genetic epileptic disease.

Two tissue chip investigations funded by the National Institutes of Health (NIH) are among the payloads launching on SpaceX’s 27th Commercial Resupply Services (CRS) mission to the International Space Station (ISS).